Mr Ben Noll

Senior Technical Specialist: Research UniSA Clinical & Health Sciences

City West Campus (HB7-25)
tel +61 8 830 21601

email Ben.Noll@unisa.edu.au

Research

Research focus

Oncology and Carcinogenesis
Pharmacology and Pharmaceutical Sciences
Clinical Sciences
Medicinal and Biomolecular Chemistry
Paediatrics and Reproductive Medicine

Highlights

Analytical evaluation and pharmacokinetic analysis of Mnk inhibitors for targeted therapy in cancer.

Research

Outputs

Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included.

Open access indicates that an output is open access.

Journal Articles

Year	Output
2025	Mekonnen, LB, Teo, T, Noll, B, Rahaman, MH, Lenjisa, J, Basnet, S, Hassankhani, R, Milne, R, Gliddon, BL, Tea, MN, Pitson, SM, Zhou, Y, Wei, L, Wang, H, Liu, J, Zhou, X, Wang, K & Wang, S 2025, 'A brain-penetrant CDK4/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma', Biomedicine and Pharmacotherapy, vol. 189, article no. 118340, pp. 1-16. Open access
2024	Mustafa, EH, Laven-Law, G, Kikhtyak, Z, Nguyen, V, Ali, S, Pace, AA, Iggo, R, Kebede, A, Noll, B, Wang, S, Winter, JM, Dwyer, AR, Tilley, WD & Hickey, TE 2024, 'Selective inhibition of CDK9 in triple negative breast cancer', Oncogene, vol. 43, no. 3, pp. 202-215. Open access 12 12 167
2023	Islam, S, Rahaman, MH, Yu, M, Noll, B, Martin, JH, Wang, S & Head, R 2023, 'Anti-Leukaemic activity of Rilpivirine Is mediated by Aurora A Kinase Inhibition', Cancers, vol. 15, no. 4, article no. 1044, pp. 1-21. Open access 5 4 3
2022	Anshabo, AT, Bantie, L, Diab, S, Lenjisa, J, Kebede, A, Long, Y, Heinemann, G, Karanjia, J, Noll, B, Basnet, SK, Li, M, Milne, R, Albrecht, H & Wang, S 2022, 'An orally bioavailable and highly efficacious inhibitor of CDK9/FLT3 for the treatment of acute myeloid leukemia', Cancers, vol. 14, no. 5, article no. 1113, pp. 1-19. Open access 12 10 23
2021	Sallustio, BC, Noll, BD, Hu, R, Barratt, DT, Tuke, J, Coller, JK, Russ, GR & Somogyi, AA 2021, 'Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients', British Journal of Clinical Pharmacology, 87, no. 10, pp. 3901-3909. 21 21
2021	Yu, M, Long, Y, Yang, Y, Li, M, Teo, T, Noll, B, Philip, S & Wang, S 2021, 'Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation', European Journal of Medicinal Chemistry, vol. 218, article no. 113391. Open access 9 8
2021	Yu, M, Teo, T, Yang, Y, Li, M, Long, Y, Philip, S, Noll, B, Heinemann, GK, Diab, S, Eldi, P, Mekonnen, L, Anshabo, AT, Rahaman, MH, Milne, R, Hayball, JD & Wang, S 2021, 'Potent and orally bioavailable CDK8 inhibitors: design, synthesis, structure-activity relationship analysis and biological evaluation', European Journal of Medicinal Chemistry, vol. 214, pp. 1-22. Open access 14 13 1
2020	Bantie, L, Tadesse, S, Likisa, J, Yu, M, Noll, B, Heinemann, G, Lokman, NA, Ricciardelli, C, Oehler, MK, Beck, A, Pradhan, R, Milne, R, Albrecht, H & Wang, S 2020, 'A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer', Gynecologic Oncology, vol. 159, no. 3, pp. 827-838. 16 18 1
2019	Abdelaziz, AM, Diab, S, Islam, S, KC Basnet, S, Noll, B, Li, P, Mekonnen, LB, Lu, J, Albrecht, H, Milne, RW, Gerber, C, Yu, M & Wang, S 2019, 'Discovery of n-phenyl-4-(1h-pyrrol-3-yl)pyrimidin-2-amine derivatives as potent mnk2 inhibitors: design, synthesis, sar analysis, and evaluation of in vitro anti-leukaemic activity', Medicinal Chemistry, vol. 15, no. 6, pp. 600-621. 6 5
2019	Lee, KJ, Tieu, W, Blanco-Rodriguez, B, Paparella, AS, Yu, J, Hayes, A, Feng, J, Marshall, AC, Noll, B, Milne, R, Cini, D, Wilce, MC, Booker, GW, Bruning, JB, Polyak, SW & Abell, AD 2019, 'Sulfonamide-based inhibitors of biotin protein ligase as new antibiotic leads', ACS Chemical Biology, vol. 14, no. 9, pp. 1990-1997. Open access 9 8
2019	Rahaman, MH, Yu, Y, Zhong, L, Adams, J, Lam, F, Li, P, Noll, B, Milne, R, Peng, J & Wang, S 2019, 'CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia', Investigational New Drugs, vol. 37, no. 4, pp. 625-635. 34 33 3
2019	Sallustio, BC, Noll, BD, Coller, JK, Tuke, J, Russ, G & Somogyi, AA 2019, 'Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation', British Journal of Clinical Pharmacology, vol. 85, no. 5, pp. 1015-1020. Open access 5 3
2018	Sweetman, MJ, Sebben, D, Noll, BD, Wang, WH, May, S, Mebberson, N, Plush, SE & Hayball, JD 2018, 'A rapid technique to determine performance and efficiency of activated carbon water filters', Water Science and Technology: Water Supply, vol. 18, no. 2, pp. 371-382. Open access 9 8
2018	Tadesse, S, Bantie, L, Tomusange, K, Yu, M, Islam, S, Bykovska, N, Noll, B, Zhu, G, Li, P, Lam, F, Kumarasiri, M, Milne, R & Wang, S 2018, 'Discovery and pharmacological characterisation of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents', British Journal of Pharmacology, vol. 175, no. 12, pp. 2399-2413. Open access 23 22 3
2017	Diab, S, Abdelaziz, AM, Li, P, Teo, T, Basnet, SK, Noll, B, Rahaman, MH, Lu, J, Hou, J, Yu, M, Le, BT, Albrecht, H, Milne, RW & Wang, S 2017, 'Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia', European Journal of Medicinal Chemistry, vol. 139, pp. 762-772. Open access 23 22
2017	O'Brien-Brown, J, Jackson, A, Reekie, TA, Barron, ML, Werry, EL, Schiavini, P, McDonnell, M, Munoz, L, Wilkinson, S, Noll, B, Wang, S & Kassiou, M 2017, 'Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists', European Journal of Medicinal Chemistry, vol. 130, pp. 433-439. Open access 32 32 6
2017	Zeleke, S, Yu, M, Mekonnen, LB, Lam, F, Islam, S, Tomusange, K, Rahaman, MH, Noll, B, MC Basnet, S, Teo, T, Albrecht, H, Milne, R & Wang, S 2017, 'Highly potent, selective, and orally bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation', Journal of Medicinal Chemistry, vol. 60, no. 5, pp. 1892-1915. Open access 72 65 9
2016	Sutton, SK, Carter, DR, Kim, P, Tan, O, Arndt, GM, Zhang, XD, Baell, J, Noll, BD, Wang, S, Kumar, N, McArthur, GA, Cheung, BB & Marshall, GM 2016, 'A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner', Oncotarget, vol. 7, no. 32, pp. 52166-52178. Open access 9 8 1

External engagement & recognition

Collaborations

External engagement & recognition

Collaborations

Organisation	Country
Guangzhou Medical University	CHINA
Imperial College of Science, Technology and Medicine	UNITED KINGDOM
Monash University	AUSTRALIA
Peter MacCallum Cancer Centre	AUSTRALIA
Private Individual	UNITED KINGDOM
Puratap Pty Ltd	AUSTRALIA
Royal Adelaide Hospital	AUSTRALIA
Shandong University	CHINA
Sydney Children's Hospital	AUSTRALIA
The Queen Elizabeth Hospital	AUSTRALIA
University of Adelaide	AUSTRALIA
University of New South Wales	AUSTRALIA
University of Newcastle	AUSTRALIA
University of South Australia	AUSTRALIA
University of Sydney	AUSTRALIA

more less

Mr Ben Noll

About me

About me

UniSA Clinical & Health Sciences

About me

Professional Associations

Research

Research focus

Highlights

Projects

Outputs

Journal Articles

Current research & highlights

External engagement & recognition

Collaborations

Collaborations

Gallery